MicroRNA-765 Enhances the Anti-Angiogenic Effect of CDDP via APE1 in Osteosarcoma

Liang, Wei; Wei, Xi; Li, Qing; Dai, Nan; Li, Chongyi; Deng, Yi; Jiang, Xuan; Tan, Xiaorong; Dai, Xiaoyan; Li, Mengxia; Xu, Cheng-Xiong; Wang, Dong; Zhong, Zhaoyang

doi:10.7150/jca.18680

Cited by 24 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, for the first time, we demonstrated that miR-765 was upregulated in the plasma of ccRCC patients after tumour resection and that ccRCC tissues had a lower expression of miR-765 than non-cancerous control tissues. MiR-765 was shown to be a tumour suppressor in osteosarcoma [23] and tongue squamous cell carcinoma [24]. Other studies indicated that miR-765 was upregulated in hepatocellular carcinoma and melanoma [28,29].…”

Section: Discussionmentioning

confidence: 99%

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

et al. 2020

View full text Add to dashboard Cite

A B S T R A C TBackground: Lipid accumulation has been highlighted in cancer development and progression, but the exact mechanism remains unclear in renal cell carcinoma (RCC). MicroRNAs (miRNAs) have been confirmed to participate in the pathological processes of cancers, including tumour occurrence and inhibition. However, the role and mechanism of miR-765 have not been elucidated in clear cell renal cell carcinoma (ccRCC). Methods: Using The Cancer Genome Atlas (TCGA) database and qRT-PCR, we investigated differences in miR-765 and proteolipid protein 2 (PLP2) expression, as well as their clinical relevance. To investigate the function of miR-765 and PLP2 in ccRCC, we performed in vitro and in vivo experiments to explore their biological functions in ccRCC. Findings: In this study, we showed that miR-765 was upregulated in the plasma of ccRCC patients after tumour resection. Consistently, ccRCC tissues had low expression of miR-765 when compared with corresponding non-cancerous tissues. Overexpression of miR-765 suppressed cell proliferation and metastasis in vitro and in vivo. Mechanistic studies demonstrated that PLP2 was a direct target gene of miR-765. PLP2 was highly expressed in ccRCC tissues, and high PLP2 levels were positively correlated with higher tumour stage and grade and poor prognosis. PLP2 expression was negatively correlated with the miR-765 level in patient samples. We further showed that PLP2 restrained the cell metastasis and proliferation induced by miR-765 and reduced the lipid-eliminating effects of miR-765 in renal cancer cells. Interpretation: Our findings suggest that miR-765 may function as a tumour suppressor and eliminate lipids in clear cell renal cell carcinoma by targeting PLP2. EBioMedicine journal homepage: www.elsevier.com/locate/ebiom that miR-765 inhibits osteosarcoma [23] and tongue squamous cell carcinoma [24]. Nevertheless, to the best of our knowledge, there is still no relevant research about the role of miR-765 in ccRCC. We found that the plasma level of miR-765 was upregulated after tumour resection in ccRCC patients and that ccRCC tissues had a low level of miR-765 compared with corresponding non-ccerous tissues. The present study systematically describes the function and role of miR-765 in ccRCC. Functionally, miR-765 inhibited RCC cell proliferation, migration and invasion in vitro and in vivo. Mechanistically, miR-765 serves as a tumour suppressor and eliminates lipids by downregulating PLP2 in ccRCC. Our findings reveal that the miR-765-PLP2 axis may be a biomarker and a therapeutic target for ccRCC. Materials and methods Patient samples and cellsThirty-six clear cell renal cell carcinoma (ccRCC) patient surgical specimens, 18 non-ccRCC (nccRCC) patient surgical specimens and 18 blood plasma samples (preoperative and operational day 7 without chemotherapy or radiotherapy for ccRCC) were obtained from

show abstract

Section: Discussionmentioning

confidence: 99%

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

et al. 2020

View full text Add to dashboard Cite

show abstract

“…SiRNAs of LINC00673, LINC00673, miRNA mimics and inhibitors were designed and synthesized by Ruibo Guangzhou. Transfection methods are described as references [8] .…”

Section: Mirna Sirna and Plasmid Transfectionmentioning

confidence: 99%

“…xenograft specimens IHC assay were performed as described previously [8]. The IHC staining score was reviewed by an expert panel of pathologists.…”

Section: Immunohistochemistry (Ihc)mentioning

confidence: 99%

LNC00673 suppresses proliferation and metastasis of pancreatic cancer via target miR-504/ HNF1A

et al. 2020

View full text Add to dashboard Cite

Pancreatic cancer is a highly invasive malignant tumor of the digestive system. To explore the mechanism of pancreatic cancer development, development, invasion and metastasis, in this study we focused on long non-coding RNA (LncRNA), which has been reported to be involved in tumorigenesis. We identified a LINC00673, which is highly correlated with the pancreatic cancer risk. LINC00673 Overexpression is associated with good survival in pancreatic cancer patients, Effects of LINC00673 on pancreatic cancer cell apoptosis, viability, migration. LINC00673 negatively correlated with miR-504 and MiR-504 overexpression promoted cancer progression in Pancreatic cancer. MiR-504 negatively correlated with HNF1A, which was highly expressed Pancreatic cancer. HNF1A inhibited cell progression in pancreatic cancer cells. LINC00673 overexpression inhibited caner progression in nude mice. Taken together, LINC00673 can through suppress miR-504/ HNF1A regulating invasion and migration in pancreatic cancer. Also, we identified miR-504 as a target of LINC00673 in pancreatic cancer and LINC00673 can be used as a novel therapeutic target for the pancreatic cancer.

show abstract

“…Therefore, further clarification concerning the expression pattern, roles and underlying molecular mechanisms of miRNAs in MM would provide novel clinical intervention tools for patients with this fatal malignancy. miR-765 is reportedly abnormally expressed and contributes to the tumorigenesis of many different types of human cancer, such as esophageal squamous cell carcinoma (24), osteosarcoma (25) and hepatocellular carcinoma (26). However, the expression pattern, specific roles and underlying mechanism of miR-765 in MM remain largely unknown.…”

Section: Introductionmentioning

confidence: 99%

microRNA‑765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6

Long

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Increasing evidence has revealed that microRNAs (miRNAs) are closely associated with multiple myeloma (MM) pathogenesis and progression. Therefore, an in-depth understanding of the biological functions of miRNAs in MM may be helpful for the identification of promising therapeutic techniques for patients with MM. miRNA-765 (miR-765) has been reported to be dysregulated in many types of human cancer. However, the expression pattern, specific roles and underlying mechanisms of miR-765 in MM remain largely unknown. In the present study, plasma miR-765 significantly increased in patients with MM and cell lines. The downregulation of miR-765 in MM cells attenuated proliferation and promoted apoptosis. Bioinformatics analysis predicted that SRY-Box 6 (SOX6) was a putative target of miR-765. This was experimentally verified using a luciferase reporter assay, reverse transcription-quantitative PCR and western blot analysis. Furthermore, plasma SOX6 was downregulated in patients with MM and the downregulation of SOX6 was inversely correlated with that of miR-765 expression. Furthermore, SOX6 knockdown markedly abrogated the effects of miR-765 underexpression on cell proliferation and apoptosis in MM. The current study demonstrated that miR-765 serves an oncogenic role in MM progression by directly targeting SOX6, suggesting that miR-765 may be a potential therapeutic target for MM prevention and treatment.

show abstract

MicroRNA-765 Enhances the Anti-Angiogenic Effect of CDDP via APE1 in Osteosarcoma

Cited by 24 publications

References 25 publications

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2

LNC00673 suppresses proliferation and metastasis of pancreatic cancer via target miR-504/ HNF1A

microRNA‑765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6

Contact Info

Product

Resources

About